Exparel (bupivacaine liposome injectable suspension) is prescribed for pain relief after surgery. The drug comes as a suspension. A healthcare professional injects this type of liquid mixture as a one ...

In its third quarter financial report, Pacira noted a 23 percent increase in Exparel net product sales, which hit $82.2 million for the quarter,. Due to recent positive coverage announcements from CMS ...

Pacira BioSciences, Inc. PCRX announced that the FDA has approved its supplemental new drug application (sNDA) for its marketed product, Exparel, to address a new indication. The latest nod from the ...

According to the American College of Surgeons, 15 million Americans undergo surgery each year. Despite this high frequency and the significant impact these procedures can have on patients, no ...

Pacira BioSciences, Inc. PCRX has made steady progress with its flagship product, Exparel, which is a liposome injection of bupivacaine indicated for a single-dose administration into the surgical ...

IMPROVE trial compares the cost of care between a standard opioid-based regimen and an EXPAREL-based multimodal regimen for postsurgical pain management PARSIPPANY, N.J.--(BUSINESS WIRE)-- Pacira ...

Please provide your email address to receive an email when new articles are posted on . Published results showed Exparel may be safe in patients aged 6 to younger than 17 years undergoing spine or ...

An injectable anesthetic may be able to dull pain after major implant surgery. A recent study found that the bupivacaine liposome injectable suspension Exparel significantly reduced pain for patients ...

MIAMI (KFSN) -- Being told your child needs open heart surgery is frightening enough. A major concern is the pain after the procedure. Now a new type of anesthesia is proving to be a real game-changer ...

Pacira Pharmaceuticals announced results from a 200-patient study evaluating the benefits of Exparel (bupivacaine liposome injectable suspension) as the foundation of a multimodal postsurgical pain ...

Becker’s ASC Review recently received a question about billing and coding for EXPAREL from Pacira Pharmaceuticals. • In 2014, the Centers for Medicare and Medicaid Services finalized a policy change ...

Pacira Pharmaceuticals, Inc.PCRX announced that it has filed a lawsuit against the FDA seeking a court ruling to defend its rights to promote Exparel for the approved indication. Exparel, Pacira's ...